General Licensing. Subject to Sections 5.9(d) and 6.3, [ * ] shall have the right to enter into a license or sublicense with any Third Party for any or all rights to any Antibody Target Candidates, Antibodies or Products [ * ], including without limitation any Out-Licensing Candidates. All consideration received or to be received from any such license, including, without limitation, all license fees, milestone payments and royalties shall be treated as [ * ], except that any consideration for [ * ] shall be allocated as provided in Sections 5.9 and 6.
Appears in 4 contracts
Samples: Collaboration Agreement (Protein Design Labs Inc/De), Collaboration Agreement (Protein Design Labs Inc/De), Collaboration Agreement (Exelixis Inc)
